Literature DB >> 2533903

The determination in plasma and pharmacokinetics of ondansetron.

P V Colthup1, J L Palmer.   

Abstract

High performance liquid chromatography has been found to be an accurate method for determination of ondansetron in plasma. Within a single assay, and between assays, the differences between theoretical and observed means obtained from analysis of spiked samples were low and good precision was obtained. The method has been used to assay several thousand samples from subjects included in pharmacokinetic studies. The pharmacokinetic profile of ondansetron has been established following single and multiple oral dosing and intravenous infusions.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2533903

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN： 0277-5379


  9 in total

Review 1.  Pharmacokinetic optimisation of antiemetic therapy.

Authors:  M Campbell; D N Bateman
Journal:  Clin Pharmacokinet       Date:  1992-08       Impact factor: 6.447

2.  Cardiovascular stability with rapid intravenous infusion of ondansetron.

Authors:  J S Heyman; M L Young; R J Bagshaw; W J Levy; R T Geer; S J Aukburg; A F Joslyn; T J Conahan
Journal:  Can J Anaesth       Date:  1993-05       Impact factor: 5.063

Review 3.  Ondansetron. Therapeutic use as an antiemetic.

Authors:  R J Milne; R C Heel
Journal:  Drugs       Date:  1991-04       Impact factor: 9.546

4.  Ondansetron pharmacokinetics in pregnant women and neonates: towards a new treatment for neonatal abstinence syndrome.

Authors:  M H Elkomy; P Sultan; B Carvalho; G Peltz; M Wu; C Clavijo; J L Galinkin; D R Drover
Journal:  Clin Pharmacol Ther       Date:  2014-12-04       Impact factor: 6.875

5.  Placental transfer of ondansetron during early human pregnancy.

Authors:  Shing-Shun N Siu; Matthew T V Chan; Tze-Kin Lau
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 6.  Ondansetron. An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting.

Authors:  Anthony Markham; Eugene M Sorkin
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

Review 7.  Ondansetron clinical pharmacokinetics.

Authors:  F Roila; A Del Favero
Journal:  Clin Pharmacokinet       Date:  1995-08       Impact factor: 6.447

8.  Concentration of ondansetron in cerebrospinal fluid following oral dosing in volunteers.

Authors:  K H Simpson; P Murphy; P V Colthup; P Whelan
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

9.  Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Ondansetron Study Group.

Authors:  C Seynaeve; J Schuller; K Buser; H Porteder; S Van Belle; P Sevelda; D Christmann; M Schmidt; H Kitchener; D Paes
Journal:  Br J Cancer       Date:  1992-07       Impact factor: 7.640
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.